Vancomycin ototoxicity and nephrotoxicity. A review.

Area of Science:

• Pharmacology
• Nephrology
• Ototoxicology

Background:

• Vancomycin, an antistaphylococcal antibiotic, has been used clinically for over 30 years.
• Early, less pure vancomycin formulations were associated with ototoxicity and nephrotoxicity.
• The correlation between therapeutic serum concentrations and these toxicities requires further clarification.

Purpose of the Study:

• To review the medical literature on vancomycin-associated ototoxicity and nephrotoxicity.
• To examine the evidence linking these toxicities to therapeutic serum vancomycin concentrations.
• To identify areas requiring further clarification regarding vancomycin toxicity monitoring.

Main Methods:

• Literature review of published reports on vancomycin ototoxicity and nephrotoxicity.
• Analysis of case studies detailing patient outcomes and serum vancomycin concentrations.
• Evaluation of factors contributing to vancomycin-induced toxicities, including co-administration of other agents.

Main Results:

• 28 reports of vancomycin-associated ototoxicity since 1958; hearing impairment often affects higher frequencies and may be reversible.
• Over half of 57 reported nephrotoxicity cases occurred early in vancomycin's use, often with pre-existing renal dysfunction or concurrent nephrotoxic agents.
• The precise incidence and correlation of nephrotoxicity with serum concentrations remain uncertain, especially with current purer formulations.

Conclusions:

• While early vancomycin formulations posed risks, current products are likely safer.
• Optimal timing for serum concentration sampling and necessity of routine monitoring require further investigation.
• Tailoring vancomycin regimens to achieve target peak (30-40 mg/L) and trough (5-10 mg/L) concentrations and avoiding co-administration of other nephrotoxic/ototoxic agents are recommended.